Please login to the form below

Not currently logged in
Email:
Password:

F2G appoints chief financial officer

Ralf Schmid brings experience from Nabriva Therapeutics

F2G Ralf SchmidManchester-based F2G Ltd has appointed Ralf Schmid as its new chief financial officer.

Schmid brings over two decades of financial management experience to the antifungal drug discovery and development company, with particular expertise in mergers and acquisitions, licensing and public and private market transactions.

He moves to F2G from Nabriva Therapeutics, where he had been a member of the management board since the Austrian biopharmaceutical company's inception in 2006.

Schmid first served as the firm's chief financial officer, before becoming chief executive officer, and most recently held the dual post of chief operating officer and chief financial officer.

 Ian Nicholson, chief executive of F2G, said: “Following our successful $60m financing, I am delighted to welcome Ralf to the F2G team.

“His strong track record in fundraising, M&A transactions and deal structuring will be invaluable as we continue to generate positive data from our clinical trials and position the company for success.”

14th July 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics